Notable Reporting: It Seems ImmunoGen, Inc. Will Go Up. Have Another Big Increase

Notable Reporting: It Seems ImmunoGen, Inc. Will Go Up. Have Another Big Increase

The stock of ImmunoGen, Inc. (NASDAQ:IMGN) is a huge mover today! About 1.38 million shares traded hands. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 77.69% since April 8, 2016 and is downtrending. It has underperformed by 83.34% the S&P500.
The move comes after 5 months positive chart setup for the $211.87M company. It was reported on Nov, 10 by We have $4.73 PT which if reached, will make NASDAQ:IMGN worth $256.36 million more.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Out of 6 analysts covering Immunogen (NASDAQ:IMGN), 2 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 33% are positive. Immunogen has been the topic of 8 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm has “Underweight” rating given on Monday, September 21 by Morgan Stanley. Leerink Swann maintained the stock with “Market Perform” rating in Wednesday, October 28 report. The firm has “Neutral” rating given on Monday, August 3 by Cantor Fitzgerald. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) earned “Outperform” rating by Oppenheimer on Wednesday, July 29. On Monday, May 2 the stock rating was maintained by Leerink Swann with “Market Perform”. The rating was upgraded by Jefferies on Wednesday, November 25 to “Buy”. The company was downgraded on Friday, April 29 by RBC Capital Markets. The firm has “Outperform” rating by RBC Capital Markets given on Monday, July 27.

According to Zacks Investment Research, “ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company’s product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.”

Insitutional Activity: The institutional sentiment increased to 1.65 in 2016 Q2. Its up 0.47, from 1.18 in 2016Q1. The ratio is positive, as 21 funds sold all ImmunoGen, Inc. shares owned while 28 reduced positions. 32 funds bought stakes while 49 increased positions. They now own 79.39 million shares or 6.04% more from 74.87 million shares in 2016Q1.
Wells Fargo And Communication Mn holds 0% or 1.45M shares in its portfolio. California Pub Employees Retirement Sys, a California-based fund reported 124,300 shares. Bb&T Securities Limited Liability Company accumulated 29,208 shares or 0% of the stock. Alexandria Capital holds 0% or 28 shares in its portfolio. Northeast Fin Consultants has 0.05% invested in the company for 34,315 shares. Spark Mgmt Ltd Limited Liability Company last reported 0.05% of its portfolio in the stock. Reliance Tru Of Delaware has 25,246 shares for 0.01% of their US portfolio. The Vermont-based Prentiss Smith And has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Blackrock Invest Mngmt Limited Liability Corporation, a New Jersey-based fund reported 318,234 shares. First Republic Management accumulated 0% or 21,849 shares. Neuberger Berman Gp Ltd Co last reported 0% of its portfolio in the stock. Millennium Mgmt Limited Liability Company holds 0.01% or 1.62 million shares in its portfolio. Wade G W & owns 33,264 shares or 0.02% of their US portfolio. Pnc Finance Gp, a Pennsylvania-based fund reported 5,277 shares. Envestnet Asset Mngmt Incorporated holds 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 46,043 shares.

Insider Transactions: Since November 2, 2016, the stock had 5 buys, and 0 insider sales for $114,068 net activity. Another trade for 16,600 shares valued at $29,598 was made by Gregory Richard J. on Wednesday, November 2. On Wednesday, November 2 the insider BARROWS CRAIG bought $17,075. The insider Johnston David Brannon bought $16,981. $4,676 worth of ImmunoGen, Inc. (NASDAQ:IMGN) was bought by LAMBERT JOHN on Wednesday, November 2. Enyedy Mark J bought $45,738 worth of stock or 25,000 shares.

Another recent and important ImmunoGen, Inc. (NASDAQ:IMGN) news was published by which published an article titled: “ImmunoGen, Inc. Waits for Data” on November 01, 2016.

IMGN Company Profile

ImmunoGen, Inc., incorporated on March 27, 1981, is a clinical-stage biotechnology firm that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Firm is engaged in the discovery of monoclonal antibody anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. The Company’s product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. The Company’s portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). The Company’s FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. It has also entered into a collaboration with Merck, under which Merck is focused on providing Keytruda (pembrolizumab) for evaluation in combination with mirvetuximab soravtansine as part of the FORWARD II study. The Firm has built a platform that continues to generate ADCs, including IMGN779, its CD33-targeting product candidate for acute myeloid leukemia (AML). IMGN779 integrates one of its deoxyribonucleic acid (DNA)-alkylating IGN payload agents and is progressing through dose escalation in a Phase I trial in AML. It is also advancing IMGN632, a preclinical CD123-targeting ADC that uses IGN payload agent with a new engineered linker and an antibody, which it is developing for hematological malignancies, including AML.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment